Erasca, Inc.
Clinical trials sponsored by Erasca, Inc., explained in plain language.
A clinical-stage biotech company developing precision oncology therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New drug combo targets Hard-to-Treat cancers
Disease control CompletedThis study tests two experimental drugs, ERAS-007 and ERAS-601, in people with advanced solid tumors that have not responded to standard treatments. The drugs are taken orally and aim to block signals that help cancer grow. The trial will first find safe doses and then check if t…
Phase 1/2 • Sponsor: Erasca, Inc. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control CompletedThis early-phase study tests a new drug called ERAS-601, alone or with other cancer treatments, in adults with advanced solid tumors that have not responded to standard therapies. The main goals are to find safe doses and check for side effects. About 90 participants will take pa…
Phase 1 • Sponsor: Erasca, Inc. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug cocktail targets Hard-to-Treat gut cancers
Disease control CompletedThis study tested a new cancer drug called ERAS-007, given by mouth, together with other targeted therapies in 101 people with advanced colorectal or pancreatic cancers that have certain gene changes. The main goals were to check safety, find the best dose, and see how the drugs …
Phase 1/2 • Sponsor: Erasca, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC